SCR-LIP-000467 · Claim · machine-readable JSON →
HLA-DQ2 is described as the principal genetic risk determinant for celiac disease, with DQ2 presentation of gliadin to CD4+ T cells central to its pathogenesis.
This single-paper claim was consolidated into general propositions (R-CLM-19); its evidence now sits under:
Claim at a glance
- Type
- clinical association
- Knowledge state
- Emerging
- Evidence certainty
- moderate (GRADE)
- Evidence
- 1 source(s)
- Answers
- 0 question(s)
- Dates
- 2026-11-17 → 2026-11-17
Structured evidence, machine-compiled — not a verdict.
Auto-compiled by the Layer 1 surveillance loop; not yet human-reviewed. anthropic/claude-opus-4.8 · 2026-11-17
Evidence over time
Evidence (1)
- The Association of HLA-DQ2 with Celiac Disease (2021) ✓ verified — contextual · review · 2021 · reading confidence: high
“HLA-DQ2 é o principal determinante genético de risco para celíaca. Apresentação de gliadina por DQ2 a células T CD4+ central na patogênese.”
The article reviews the HLA-DQ2–celiac disease association but makes no mention of lipedema; it is on-topic for the celiac/HLA component only and does not test any link to lipedema, so it provides background context rather than direct evide
Context (PECO)
Answers these questions
- Not yet linked to a question.
Gaps & caveats
Auto-ingested single source; not yet human-reviewed.
Change log
- 2026-11-17 — created · auto-ingested for SQ-LIP-000009
- 2026-11-20 — consolidated · SQ-LIP-000009: evidence moved to SCR-LIP-000626